Gain insight from industry experts
Whether you have questions about the evolving role of screening and testing in the primary care setting or you are looking for insight on appropriate diagnosis, clinical care and treatment protocols, you'll find expert answers and advice here. The links below take you to live presentations and articles covering primary care topics.
Prescription Drug Monitoring
Dr. Inderpal Randhawa, Attending Physician, Southern California Allergy, Asthma and Pulmonology Specialists, discusses the nature of these challenges and reviews approaches to help in timely, accurate diagnosis of allergic disease.
Dr. Cox, Associate Clinical Professor of Medicine, Nova Southeastern University, discusses the rising trend in allergic disease and reviews diagnostic and treatment strategies, which can help reduce its burden on patients and the healthcare system.
Is It Truly an Allergy? Making the Differential Diagnosis
Inderpal Randhawa, MD, discusses the prevalence of allergic diseases in the U.S. and how diagnostic testing can help clinicians make an accurate diagnosis of allergic and nonallergic conditions to guide appropriate therapeutic interventions. Contains a number of case studies.
Allergy Diagnostic Testing: The Nuts and Bolts
Linda S. Cox, MD, an allergist and immunologist treating both adult and pediatric patients, will focus on best practices and current recommendations regarding the appropriate use of allergy diagnostics, and allergy diagnostic methods and technologies.
BRCA Mutation Testing—Identifying Risk for Hereditary Breast and Ovarian Cancer
Dr. Patrick James, Senior Medical Director, Quest Diagnostics, discusses how genetic testing provides physicians with valuable information to help identify patients with Hereditary Breast and Ovarian Cancer (HBOC) syndrome and provides a basis for potentially lifesaving interventions. He reviews how technology has evolved to offer physicians different testing options and more precise information regarding their patients’ potential risk.
Breast Cancer: Webinars
BRCAvantage™: An In-depth Discussion
Quest Diagnostics’ Frederic Waldman, MD, and Linda Cheng, CGC, discuss the rationale behind the breast cancer expanded menu, help the participants understand the benefits of the expanded test offering, and describe the technology and design of BRCAvantage™ Plus.
Omega-3 and Omega-6 Fatty Acids—Measuring Blood Levels to Help Manage Cardiovascular Risk
Dr. Robert Superko reviews the evidence relating to omega-3 intake and discusses why measuring blood concentration levels can provide a basis for reducing cardiovascular risk.
Cardiovascular Disease—A Comprehensive Approach to Manage the Risks of Cardiac Events
Dr. Cesar Molina, Heart and Vascular Associates, Mountain View, California, discusses the significance of residual risk and outlines how a more comprehensive approach to patient management, beyond a single focus on reducing LDL-C, can reduce clinical events in at-risk populations.
Advanced Lipid Testing: Enabling a More Accurate Assessment of Cardiovascular Disease Risk
Dr. Ronald Krauss, Senior Scientist and Director of Atherosclerosis Research at Children’s Hospital Oakland Research Institute, cautions that physicians should not rely exclusively on LDL cholesterol for assessing or managing risk. He discusses how the direct measurement of lipoprotein particles, using ion mobility analysis, and an assessment of a patient’s overall lipoprotein particle profile provide a basis for more accurate assessment of risk and monitoring of therapy.
Cardiovascular Disease: Webinars
Cardio IQ in Primary Care: Uncovering the Hidden High-Risk Patient
Dr. John Corso presents two cardiovascular patient case studies that highlight the value of uncovering residual risk in the management of cardiovascular disease. He also shares his insight into their clinical care and treatment protocols.
Improving Cardiovascular Risk Assessment in 2014
Dr. Douglas Jacoby helps participants understand when to consider advanced risk assessment and blood tests, what assessments to use, and the future therapeutic choices beyond statins.
Review of Clinical Research and the Effective Use of Omega -3 &-6 Fatty Acids in Patient Management
Robert Superko, MD, and Michael Caulfield, PhD, discuss the current clinical research on the use of omega-3 and omega-6 supplementation and their link to decreased risk of cardiovascular events, including sudden cardiac death. They will also discuss the clinical management of patients, including the use of the omega-3 and omega-6 fatty acid laboratory test as a marker of cardiovascular risk.
Beyond LDL Cholesterol, Residual Risk and the Appropriate Clinical Utility of Advance CVD Tests
Robert Superko, MD, discusses the clinical value of advanced lipid testing, the 2013 ACC/AHA guidelines, the impact on cardiovascular clinical practice, the technological evolution of ion mobility and the current clinical research being done to support advanced lipid subclass measurement for CVD risk.
Advanced Insights into Residual Cardiovascular Risk—Another Perspective
Dr. Ian Levenson brings his unique perspective to the discussion of the benefit of going beyond the traditional lipid panel. He will review the value of advanced cardiovascular testing and how it can be applied to a large practice that focuses on prevention, general medicine and cardiovascular risk.
Ion Mobility: Advance Lipid Analysis for Management of Cardiovascular Risk
Ronald M. Krauss, MD, and Robert Superko, MD, present an engaging discussion on the role of advanced lipid testing in treating patients with cardiovascular disease. They provide a unique insider’s view on the latest technological advancement, ion mobility, as Dr. Krauss developed ion mobility as the next generation in lipid subclass separation.
Advanced Insights into Residual Cardiovascular Risk
Dr. Cesar Molina will discuss residual risk and the need to reclassify patients with existing cardiovascular disease, why cardiovascular disease exists despite managing patients to lipid goals and the unique solution of the core offering from Quest Diagnostics Cardio IQ.
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Disease
Chip Lavie, MD, discusses the established and emerging clinical evidence supporting the benefits of omega-3 fatty acids for cardiovascular health as well as the potential clinical utility of monitoring omega-3 levels.
West Nile Virus 2012: What You Need to Know
Jay M. Lieberman, MD discusses the history of West Nile Virus (WNV) infection in the US and the current 2012 outbreak, with particular emphasis on the recommended diagnostic evaluations to effectively identify this infection and appropriately manage patients.
Common Infectious Diseases: Health Trends
Health Trends™ – H1N1 Influenza
Quest Diagnostics is the first independent lab in the US to perform H1N1 laboratory testing and provides two H1N1 test kits that the FDA has authorized for emergency use by other qualified molecular laboratories.
U.S. Patients Improved Diabetes Control Over 5-Year Period
The Quest Diagnostics Diabetes Report shows that people with diabetes are doing a better job of managing their disease. The proportion of test results deemed to represent good diabetes control increased from 36% in early 2001 to a high of 56% in late 2005.
A Quest Diagnostics Health Trends™ study finds that many pregnant women are not screened for two common sexually transmitted diseases. The study, based on test results of 1.3 million pregnant women, found that only 59% and 57% of women were tested at least once for chlamydia and gonorrhea, respectively, during their pregnancy. The American Journal of Obstetrics and Gynecology, a peer-reviewed medical journal, has published the study online.
Hepatitis C—The Primary Care Physician’s Role in Reducing the Epidemic’s Impact
Dr. Paul Sax, Clinical Director, Division of Infectious Disease, Brigham and Women’s Hospital, and professor of medicine at Harvard Medical School, discusses the critical role of primary care physicians in identifying those infected with HCV and reducing the burden of chronic liver disease through timely intervention.
Hepatitis C: How Broad Screening and New Therapies Can Transform the Disease Burden
Dr. Bruce Bacon, James F. King, MD, Endowed Chair in Gastroenterology, Saint Louis University School of Medicine, discusses why the advent of new, effective therapies, combined with more comprehensive screening, promise to transform the management of HCV and radically reduce the burden of the disease in the U.S.
Hepatitis C—A Review of the CDC Recommendations for Birth-Cohort Screening
Dr. Nancy Reau, Associate Professor of Medicine, University of Chicago, reviews the recently issued recommendations, and discusses their significance in the context of other trends in Hepatitis C patient management: the increasing burden of the disease and the high cure rates now achievable.
Hepatitis C—Recent Advances in Diagnostics and Therapy
Recent advances in diagnosis and treatment are providing physicians with new options for managing patients with chronic HCV. Dr. Rick Pesano, Medical Director, Infectious Diseases, Quest Diagnostics, discusses how these developments can help physicians predict response to therapy and direct treatment for nonresponders.
Hepatitis C: What the Primary Care Provider Needs to Know
Paul E. Sax, MD, explains the indications and rationale for HCV testing and helps attendees understand how to conduct a baseline clinical and laboratory evaluation and learn the basics of the rapidly changing HCV treatment options.
An Update on Hepatitis C: Diagnosis, Management and Therapy
Nancy Reau, MD, reviews the CDC screening guidelines, examines the natural history of hepatitis C, and discusses the evolution of current and near-term treatment.
Hepatitis C: The Revolution Has Begun!
Bruce Bacon, MD, explains the importance of hepatitis C screening and the new guidelines, and describes the significant changes to treatment and their important impact on patient care.
Fighting a Growing Epidemic: Screening for and Treating HCV
Nancy Reau, MD, discusses the growing epidemic of hepatitis C infection in the U.S., including the recommendation that all people born between the years 1945 and 1965 be screened and have appropriate diagnostic workups, and recommendations regarding patient counseling and treatment options. ASCLS P.A.C.E. credits available through August 27, 2013.
Laboratory Testing in the Treatment of HCV: New Drugs, New Tests, New Rules
Douglas T. Dieterich, MD, will focus on current guidelines and recommended strategies for treating patients with chronic hepatitis C viral (HCV) infection, including protease inhibitors and response-guided therapy, HCV RNA assays, IL28B genotyping and resistance testing.
HIV Management—The Evolving Role of the Primary Care Physician
Dr. Paul Sax, Clinical Director, Division of Infectious Disease, Brigham and Women’s Hospital, and professor of medicine at Harvard Medical School, reviews the role PCPs should play in HIV screening and diagnosis and discusses the rationale for co-management of patients by PCPs and HIV infectious disease specialists.
A New Algorithm for HIV Laboratory Testing
Dr. Bernard Branson, Associate Director for Laboratory Diagnostics, CDC Division of HIV/AIDS Prevention, discusses the rationale for developing the new algorithm. He explains how it will enable earlier detection of HIV infection and reduce the number of indeterminate results, leading to improved patient management and long-term outcomes.
Current Issues and Hot Topics in HIV Treatment & Diagnostics
In January 2011, the U.S. Department of Health and Services (DHHS) published revised “Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents.” Recent European Consensus Panel Guidelines endorsed genotypic tropism testing as a viable alternative to phenotype tropism testing. The current DHHS treatment guidelines do not yet endorse the European approach and recommend phenotypic tropism testing when available. The field of tropism testing continues to evolve and should remain a hot topic for the near future.
HIV Care 2013: The Role of the Primary Care Provider
Paul E. Sax, MD, discusses screening for HIV in the primary care setting, best practices related to the management of patients with HIV infection by primary care physicians, and appropriate strategies for co-management with infectious disease specialists.
HIV Laboratory Diagnosis: New Tests and a New Algorithm
Bernard Branson, MD, will explain why it is essential to detect acute HIV infection, how to differentiate assays and help the attendee understand the rationale behind testing.
H. pylori: Gaps in Care
Aamir Ali, MD, provides important information to medical professionals on the appropriate diagnosis and treatment for early onset of H. pylori and why testing prior to prescribing a proton pump inhibitor is essential for optimal patient care and helps attendees understand the importance of the eradication of H. pylori.
Appropriate Use of Proton Pump Inhibitors
M. Aamir Ali, MD, an expert in the area of gastroenterology, provides important information to medical professionals on the appropriate use of PPIs, covers the importance of PPI use as an integral part of a test and treatment strategy for H. pylori, and identifies risks and poor patient outcomes associated with overuse.
How Can Prescription Drug Monitoring Help Identify Abuse?
F. Leland McClure, PhD, Director of the Pain Management program at Quest Diagnostics, discusses how monitoring patients who are being treated for chronic pain can help reduce drug abuse/misuse and diversion, interpreting drug test results properly and why it’s important for physicians to have a trusted laboratory partner when conducting drug screening and confirmations.
Prescription Drug Abuse - Real Physicians Speak Out
The following are interviews with real physicians discussing their experiences with prescription drug abuse.
Prescription Drugs in America 2011: Are We Really Doing No Harm?
Robert M. Stutman, former DEA Special Agent, discusses prescription drug abuse/misuse among teens and young adults in the US and what healthcare professionals and parents can do to help reduce it. ASCLS P.A.C.E. credits through March 1, 2012.
Urine Drug Testing for Patients With Chronic Pain
Bill McCarberg, MD, founder of the chronic pain management program at Kaiser Permanente San Diego, discusses the best practices related to the use of urine drug testing in the management of patients being treated for chronic pain.
Prescription Drug Monitoring: Expert Insights
What’s Best When Choosing a Prescription Drug Monitoring Program?
With 100 million Americans experiencing chronic pain and the subsequent increase in prescriptions to improve their quality of life, the abuse of prescription medications has become a national issue. Prescription drug abuse now outpaces cocaine abuse. The weight of the question of prescription compliance places the physician at the frontline of finding a solution to the issue.
Prescription Drug Abuse: Stemming the Tide of a New Epidemic
According to Robert Stutman, former special agent in the U.S. Drug Enforcement Agency (DEA) and one of the nation’s top experts on drug abuse, we are in the midst of the worst drug epidemic seen in the U.S. in the past fifty years. Sadly, the drugs involved are not illegal drugs such as cocaine or heroin, but legal drugs often obtained from family members, who have been prescribed them by physicians.
New Trends in Prescription Drug Monitoring
Dr Bill McCarberg, Adjunct Assistant Clinical Professor at the University of California, San Diego and Founder of the Chronic Pain Management Program at Kaiser Permanente San Diego reviews these issues and looks ahead to developments, which hold promise for more effective treatment.
Prescription Drug Monitoring: Health Trends
Prescription Drug Misuse in America
The latest Quest Diagnostics Health Trends™ report provides Diagnostics Insights in Managing the Drug Epidemic in the United States
Rheumatoid Arthritis and Psoriatic Arthritis: The Role of Laboratory Testing in Disease Management
Dr. Martin Bergman, Clinical Associate Professor of Medicine, Drexel University College of Medicine, reviews the role of laboratory testing in diagnosis, screening and monitoring drug toxicity. He also discusses how recent advances have increased testing accuracy, helping support early diagnosis and early intervention.
14-3-3eta (η) Protein—A New Biomarker for Rheumatoid Arthritis
Dr. Maksymowych notes that one of the challenges in the field of inflammatory arthritis, especially at the primary care level, has been the limited number of diagnostic tests available. He notes that there is relatively limited training for primary care physicians with respect to the diagnostic evaluation of musculoskeletal diseases in general, and the identification of inflammatory joint disorders in particular, resulting in patients presenting with more advanced disease.
Rheumatoid Arthritis: Webinars
New Biomarker 14-3-3η: Advances in Diagnosing Early Rheumatoid Arthritis and Differentiating Osteoarthritis
Walter Maksymowych, MD, details the differences between rheumatoid arthritis and osteoarthritis, and discusses the limitation of current markers and the benefits of the 14-3-3η biomarker.
Laboratory Testing in the Diagnosis and Management of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
Martin J. Bergman, MD, discusses the seriousness of a diagnosis of rheumatoid arthritis for patients who are afflicted and the appropriate use and limitations of laboratory testing in the diagnosis and monitoring for rheumatoid disease activity.
The Role of Interferon-Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis
Dr. Richard Clark, Scientific Director of Microbiology/Virology, Quest Diagnostics Nichols Institute, Chantilly, reviews current issues in the field of TB and discusses how the recent introduction of interferon-gamma release assays (IGRAs) is helping clinicians manage the disease.
The Most Widely Misunderstood Diagnostic Test: An Update
Lee B. Reichman, MD, MPH, provides an overview of latent tuberculosis epidemiology, testing and treatment, including an in-depth discussion of the tuberculin skin test (which he considers to be the most widely misunderstood diagnostic test) and the clinical utility and cost-effectiveness of interferon gamma release assays (IGRAs) for the detection of latent tuberculosis.